Abstract
Here, we describe the case of a 43-year-old male patient with a metastatic parathyroid carcinoma who underwent dual-tracer whole-body positron emission tomography/computed tomography (PET/CT) with [18F]fluorocholine and fluorodeoxyglucose ([18F]FDG) for staging. [18F]FDG PET/CT detected multiple cervical and mediastinal lymph nodal lesions with increased tracer uptake, whereas [18F]fluorocholine PET/CT detected increased tracer uptake on cervical and mediastinal lymph nodal lesions and bone and lung lesions with a better evaluation of metastatic spread. Due to these imaging findings, the patient underwent systemic treatment with chemotherapy. This case demonstrates the added value of dual-tracer PET/CT in this rare metastatic tumor.
Keywords: positron emission tomography (PET), nuclear medicine, hybrid imaging, dual-tracer, choline, FDG, parathyroid carcinoma
Figure 1.
A 43-year-old male patient with a diagnosis of parathyroid carcinoma after left parathyroidectomy underwent dual-tracer PET/CT with [18F]FDG and [18F]fluorocholine for staging. The delay between the two PET/CT scans was about one month ([18F]FDG PET/CT as first examination and [18F]fluorocholine PET/CT as second scan). [18F]FDG PET/CT was performed 60 min after the injection of 213 MBq of [18F]FDG. [18F]fluorocholine PET/CT was performed 45 min after the injection of 200 MBq of [18F]fluorocholine. CT was performed with the injection of iodinated contrast media. Qualitative criteria for PET image analysis were used for both tracers: areas of increased tracer uptake compared to the background were considered abnormal, excluding the sites of physiological tracer uptake. [18F]fluorocholine maximum intensity projection (MIP) PET image and axial fused PET/CT images showed multiple areas of abnormal tracer uptake corresponding to multiple cervical and mediastinal lymph nodal lesions (green arrows), several bone lesions in the spine and the hip (red arrows) and right pulmonary lesions (blue arrows). [18F]FDG maximum intensity projection (MIP) PET image and axial fused PET/CT images showed increased tracer uptake in multiple cervical and mediastinal lymph nodal lesions (green arrows). Bone (red arrows) and pulmonary (blue arrows) lesions did not show significant [18F]FDG uptake. Due to these dual-tracer PET/CT imaging findings, in particular due to the additional lesions detected by [18F]fluorocholine PET/CT compared to [18F]FDG PET/CT, a diagnosis of metastatic parathyroid carcinoma with metastatic spread to the lymph nodes, bone and lung was achieved and the patient underwent systemic treatment. Parathyroid carcinoma is a rare endocrine neoplasm with possible metastatic spread. An adequate staging with imaging methods is the mainstay for the choice of treatment [1]. Hybrid imaging methods combine morphological and functional information in the same session. In this regard, [18F]FDG PET/CT, the most used PET method in oncology, has been evaluated in patients with parathyroid carcinoma and provides additional information compared to conventional imaging [2]. [18F]fluorocholine PET/CT evaluating the membrane cell turnover is an efficient and well-recognized imaging tool to localize parathyroid adenomas [3]. Conversely, scarce information is available on patients with parathyroid carcinoma [4,5,6]. The illustrated case clearly demonstrates a superior advantage of the dual-tracer [18F]fluorocholine/[18F]FDG PET/CT for the correct evaluation of metastatic spread in patients with parathyroid carcinoma. Even if dual-tracer PET/CT is associated with increased costs and radiation exposure, this imaging approach could be used for staging these rare tumors if both PET radiopharmaceuticals are available. Compared to neuroendocrine and thyroid tumors, there are no prospective studies on dual-tracer PET/CT in parathyroid carcinoma due to the rarity of this disease [7]. Comparative studies on the use of [18F]FDG PET/CT and [18F]fluorocholine PET/CT are needed to understand which is the best PET tracer for this rare tumor and when dual-tracer PET/CT should be performed.
Author Contributions
Conceptualization, G.T. and M.C.; formal analysis, C.M.I., G.P. and M.C.; data curation, M.C.; writing—original draft preparation, G.T.; writing—review and editing, C.M.I.; supervision, L.G. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Written informed consent has been obtained from the patient to publish this paper.
Data Availability Statement
The data presented in this article are available on request from the corresponding author.
Conflicts of Interest
The authors declare no conflicts of interest.
Funding Statement
This research received no external funding.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Eldaya R.W., Calle S., Wong F.C., Learned K.O., Wintermark M. Parathyroid carcinoma: Imaging features of initial presentation and recurrence. A single center experience. Neuroradiol. J. 2024;37:92–106. doi: 10.1177/19714009231212361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Evangelista L., Sorgato N., Torresan F., Boschin I.M., Pennelli G., Saladini G., Piotto A., Rubello D., Pelizzo M.R. FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World J. Clin. Oncol. 2011;2:348–354. doi: 10.5306/wjco.v2.i10.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Treglia G., Rizzo A., Piccardo A. Expanding the clinical indications of [18F]fluorocholine PET/CT in primary hyperparathyroidism: The evidence cannot be evaded. Eur. J. Nucl. Med. Mol. Imaging. 2024;51:1345–1348. doi: 10.1007/s00259-023-06573-x. [DOI] [PubMed] [Google Scholar]
- 4.Morand G.B., Helmchen B.M., Steinert H.C., Schmid C., Broglie M.A. 18F-Choline-PET in parathyroid carcinoma. Oral Oncol. 2018;86:314–315. doi: 10.1016/j.oraloncology.2018.09.009. [DOI] [PubMed] [Google Scholar]
- 5.Deandreis D., Terroir M., Al Ghuzlan A., Berdelou A., Lacroix L., Bidault F., Troalen F., Hartl D., Lumbroso J., Baudin E., et al. 18Fluorocholine PET/CT in parathyroid carcinoma: A new tool for disease staging? Eur. J. Nucl. Med. Mol. Imaging. 2015;42:1941–1942. doi: 10.1007/s00259-015-3130-6. [DOI] [PubMed] [Google Scholar]
- 6.Hatzl M., Röper-Kelmayr J.C., Fellner F.A., Gabriel M. 18F-Fluorocholine, 18F-FDG, and 18F-Fluoroethyl Tyrosine PET/CT in Parathyroid Cancer. Clin. Nucl. Med. 2017;42:448–450. doi: 10.1097/RLU.0000000000001652. [DOI] [PubMed] [Google Scholar]
- 7.Treglia G., Kroiss A.S., Piccardo A., Lococo F., Santhanam P., Imperiale A. Role of positron emission tomography in thyroid and neuroendocrine tumors. Minerva Endocrinol. 2018;43:341–355. doi: 10.23736/S0391-1977.17.02742-0. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data presented in this article are available on request from the corresponding author.